Agreement Provides for Easy Access to H2L2 Platform Use with LakePharma’s Discovery and Development Services

BELMONT, Calif. and CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, June 5, 2018 - LakePharma and Harbour Antibodies BV, a Harbour BioMed subsidiary, today announced a technology partnership providing LakePharma the right to utilize Harbour Antibodies’ patented, H2L2 transgenic mouse platform in its therapeutic antibody discovery service offerings to clients in pharmaceutical and therapeutic biotechnology companies.

Harbour Antibodies’ patented H2L2 transgenic mice produce classical antibodies (two heavy and two light chain immunoglobulins) with fully human variable regions. In response to antigen challenge, the engineered mice produce in vivo affinity-matured, target-specific human antibodies with low risk for immunogenicity.  The H2L2 platform has been used by more than thirty companies and organizations for antibody discovery. To date, two antibodies generated by the platform have entered clinical trials.

Hua Tu, Ph. D., Founder and Chief Executive Officer of LakePharma, commented: “Our clients are increasingly looking for accessible transgenic mouse platforms to discover unique therapeutic antibody candidates.  We are excited to bundle the H2L2 technology, which has established a strong track record of success, into our high-quality antibody discovery service. This partnership provides pharma and biotech companies with unprecedented capacity and flexibility to discover fully human therapeutic antibodies via LakePharma’s hybridoma-driven antibody discovery engine.”

“Harbour Antibodies is delighted to team up with LakePharma in offering the H2L2 platform in a unique business model,” said Dr. Jingsong Wang, CEO of Harbour BioMed. “Our approach is structured to facilitate easy access to the H2L2 platform through a pre-negotiated technology evaluation license and to readily integrate with LakePharma’s services.”

About LakePharma

LakePharma is the leading US-based biologics company specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, bioanalytics and µBIOMANUFACTURINGSM biologics manufacturing services for Phase 1 clinical trials. LakePharma focuses on integrated platforms to support projects throughout the drug discovery process. LakePharma offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal.

For more information, please visit www.lakepharma.com.

Contacts

Walter Tian
VP, Commercial Operation
LakePharma
Walter.tian@lakepharma.com

About Harbour Antibodies

Harbour Antibodies is a fully owned subsidiary of Harbour BioMed, a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases (www.harbourbiomed.com). Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: (1) mice that generate antibodies comprised of two heavy chains and two light chains (H2L2) with fully human variable regions; and (2) mice that generate novel “heavy chain only” antibodies (HCAb). The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable drug-like properties.

For additional information, please visit www.harbourantibodies.com 

About Harbour BioMed

 
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

 
The Company’s proprietary antibody technology platforms Harbour Mice^® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. 

For further information, please refer to www.harbourbiomed.com

Contacts

Timothy Miller
Harbour Antibodies
90 Bridge Street, Suite 100
Newton, MA 02478, USA
timothy.miller@harbourbiomed.com